Suchen
Gyre Therapeutics Inc
GYREZur Watchlist hinzufügen
7.340USD
+0.820+12.58%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
670.67MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Gyre Therapeutics Inc Unternehmen
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Gyre Therapeutics Inc Informationen
BörsenkürzelGYRE
Name des UnternehmensGyre Therapeutics Inc
IPO-datumApr 12, 2006
CEOZhang (Ping)
Anzahl der mitarbeiter574
WertpapierartOrdinary Share
GeschäftsjahresendeApr 12
Addresse12770 High Bluff Drive, Suite 150
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92130
Telefon18585677770
Websitehttps://www.gyretx.com/
BörsenkürzelGYRE
IPO-datumApr 12, 2006
CEOZhang (Ping)
Führungskräfte von Gyre Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.81M
--
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
15.00K
--
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Mr. Gordon G. Carmichael, Ph.D.
Mr. Gordon G. Carmichael, Ph.D.
Independent Director
Independent Director
--
--
Dr. Renate Parry, Ph.D.
Dr. Renate Parry, Ph.D.
Independent Director
Independent Director
--
--
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ping Zhang
Mr. Ping Zhang
Executive Chairman of the Board, Interim Chief Executive Officer
Executive Chairman of the Board, Interim Chief Executive Officer
--
--
Dr. Dan Weng
Dr. Dan Weng
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.81M
--
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
15.00K
--
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Mr. Gordon G. Carmichael, Ph.D.
Mr. Gordon G. Carmichael, Ph.D.
Independent Director
Independent Director
--
--
Dr. Renate Parry, Ph.D.
Dr. Renate Parry, Ph.D.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Gyre Therapeutics Inc?
Die fünf größten Anteilseigner von Gyre Therapeutics Inc sind: Mr. Songjiang Ma
Wie viele Institutionen halten Anteile an Gyre Therapeutics Inc (GYRE)?
Mit Stand vom 2026Q1 halten 123 Institutionen Anteile an Gyre Therapeutics Inc, mit einem Gesamtmarktwert von etwa 4.60M, was 4.74% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1255247.00 gestiegen.
Was ist die größte Einnahmequelle von Gyre Therapeutics Inc?
Am 2026Q1 erzielte das Geschäft mit ETUARY für Gyre Therapeutics Inc den höchsten Umsatz in Höhe von 27.69M, was 90.61% des Gesamtumsatzes entspricht.